AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Thursday, Digital Look reports. They currently have a £102 ($133.26) price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of 44.09% from the stock’s previous close.
A number of other research firms have also recently issued reports on AZN. Kepler Capital Markets set a GBX 9,200 ($120.20) price target on shares of AstraZeneca and gave the stock a “buy” rating in a report on Monday, December 14th. Barclays set a £100 ($130.65) price target on AstraZeneca and gave the stock a “buy” rating in a research report on Monday, March 22nd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell reissued a “buy” rating on shares of AstraZeneca in a report on Wednesday, February 24th. Credit Suisse Group set a GBX 9,000 ($117.59) target price on AstraZeneca and gave the stock a “buy” rating in a report on Wednesday. Finally, Jefferies Financial Group set a GBX 8,850 ($115.63) price target on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, March 16th. Five analysts have rated the stock with a sell rating and fifteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of GBX 8,759.44 ($114.44).
Shares of AstraZeneca stock traded down GBX 20 ($0.26) during midday trading on Thursday, hitting GBX 7,079 ($92.49). The company had a trading volume of 3,012,933 shares, compared to its average volume of 2,479,357. The company has a fifty day simple moving average of GBX 7,119.04 and a 200 day simple moving average of GBX 7,708.71. The stock has a market cap of £92.93 billion and a price-to-earnings ratio of 29.06. The company has a quick ratio of 0.67, a current ratio of 0.96 and a debt-to-equity ratio of 145.24. AstraZeneca has a 12-month low of GBX 6,736 ($88.01) and a 12-month high of £101.20 ($132.22).
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Featured Story: Front-End Load
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.